Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 444 record(s)

Req # A-2022-001016

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-109293-438.

Organization: Health Canada

11 page(s)
June 2023

Req # A-2022-001149

Adverse Drug Reactions (ADRs). Report numbers: E2B_05390581, E2B_05387196, E2B_05404106, E2B_04238483, E2B_05414596, E2B_05374871, 000994163, E2B_05395217, E2B_05250178, E2B_05387214.

Organization: Health Canada

146 page(s)
June 2023

Req # A-2022-001254

Adverse Drug Reactions (ADRs) for ADDERALL XR. Report numbers: 001014527, 001014585. ADRs for MESALAZINE. Report numbers: E2B_05856871, E2B_05825841, 001021058, 001021238, 001017639, 001021244, 001016207, 001016211.

Organization: Health Canada

33 page(s)
June 2023

Req # A-2022-001256

Adverse Drug Reaction (ADR) for AGALSIDASE ALFA. Report number: E2B_05845814. ADRs for MEZAVANT. Report numbers: E2B_05870258, E2B_05864070. ADRs for LANSOPRAZOLE. Report numbers: E2B_05853179, E2B_05844531, E2B_05840815, 001021389, E2B_05875371, E2B_05874054.

Organization: Health Canada

333 page(s)
June 2023

Req # A-2022-001289

Adverse Drug Reactions (ADRs). Report numbers: E2B_02781314, E2B_05141186, E2B_05275584, 000989134.

Organization: Health Canada

80 page(s)
June 2023

Req # A-2022-001298

Adverse Drug Reactions (ADRs). Report numbers: E2B_05825319, E2B_05841349, E2B_05853179, E2B_05866227.

Organization: Health Canada

131 page(s)
June 2023

Req # A-2022-001323

Adverse Drug Reactions (ADRs). Report numbers: E2B_05483510, E2B_05777998.

Organization: Health Canada

38 page(s)
June 2023

Req # A-2022-001341

Adverse Drug Reactions (ADRs). Report numbers: E2B_05884097, 001018450, E2B_05886951, E2B_05888011, E2B_05900596, E2B_05900633, E2B_05926576, E2B_05936764, E2B_05945935.

Organization: Health Canada

170 page(s)
June 2023

Req # A-2022-001381

Adverse Drug Reactions (ADRs). Report numbers: E2B_04238483, 001019426, 001018601, E2B_05766145.

Organization: Health Canada

90 page(s)
June 2023

Req # A-2022-001396

Adverse Drug Reactions (ADRs). Report numbers: E2B_05843577, E2B_05827824, E2B_05850071, E2B_05858657, E2B_05847252, 001013763, E2B_05874043, E2B_05859755.

Organization: Health Canada

288 page(s)
June 2023
Date modified: